The FDA has rejected Clene Nanomedicine's application for accelerated approval for the experimental drug ALS drug, CNM-Au8, citing insufficient evidence.
Clinically significant ILD is believed to occur in 5%-10% of patients with RA, but robust data are lacking on how to best predict which patients face the highest risk for RA-associated ILD.
Imaging and other tools that take advantage of developing understanding of migraine pathophysiology could eventually address difficulties in diagnosing and treating the condition.
"Tape strips can provide important clues to when and which drugs to use in HS in patients with both early and late disease, which can change clinical practice."